Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine
AssigneeBavarian Nordic A/S
InventorsRobin Steigerwald, Markus Kalla
Life of this patent
Estimating the term…
Abstract
The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same. In particular, the invention relates to recombinant MVA comprising a nucleotide sequence encoding for a structural protein of an equine encephalitis virus (EEV) excluding encoding for a capsid protein of the EEV, a composition in particular a pharmaceutical composition, a vaccine or kit comprising the recombinant MVA, uses and methods thereof e.g., suitable for treating and/or preventing a western, Venezuelan, and/or eastern equine encephalitis virus caused disease.
Claims20
A recombinant modified vaccinia virus Ankara (MVA) comprising:
- (a) a poxviral promoter operably linked to a first nucleotide sequence encoding a structural polyprotein of an Eastern equine encephalitis virus, wherein the nucleotide sequence encoding the capsid protein for said virus is excluded;
- (b) a poxviral promoter operably linked to a second nucleotide sequence encoding a structural polyprotein of a Venezuelan equine encephalitis virus, wherein the nucleotide sequence encoding the capsid protein for said virus is excluded;
- and
- (c) a poxviral promoter operably linked to a third nucleotide sequence encoding a structural polyprotein of a Western equine encephalitis virus, wherein the nucleotide sequence encoding the capsid protein for said virus is excluded.
Dependencies are inferred from the claim text.